Experimental Quintuple Agonist Drug Cuts Weight More Than Ozempic in Mice

A new experimental drug for obesity and diabetes showed strong results in early mouse trials, outperforming popular treatments like Ozempic.

Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in Nature, examined GLP-1-GIP-Lani. The drug pairs GLP-1 and GIP, two hormones that control appetite and blood sugar, with PPAR activity to boost insulin sensitivity, cut inflammation, improve fat metabolism and support liver health.

The research team, led by Professor Timo D. Muller at Helmholtz Munich, described the drug as a quintuple agonist targeting five receptor systems. In a press release, Muller called it a "Trojan horse": the incretin hormones deliver it into target cells, where the PPAR component activates to help the body process insulin, fat and inflammation better.

This setup allows a much lower dose, potentially cutting side effects. "A major advantage is the amount," Muller said. "Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower."

The study used mouse models with diabetes-induced obesity, insulin resistance and genetic obesity. The compound reduced body weight, food intake, fat mass, blood sugar and insulin issues more than GLP-1 and GIP alone. It also beat semaglutide. Gastrointestinal side effects matched those of existing therapies.

"We see a principle with strong effects in the animal model — now the task is to optimize the approach for humans and move it toward the clinic," Muller said in the release.

Dr. Peter Balazs, a hormone and weight-loss specialist in New York and New Jersey, said the drug hits obesity and insulin resistance at multiple points, including the brain, pancreas and metabolic tissues. "This is a novel mechanism because it's not just relying on a higher dose of an existing drug," he told Fox News Digital.

"Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an 'appetite brake' and a metabolic engine," he added. Unlike traditional GLP-1 drugs that mainly curb appetite, slow stomach emptying and raise insulin, this one also improves insulin sensitivity in liver and muscle, reduces fat tissue inflammation and reshapes lipid metabolism.

"The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure," Balazs said.

Balazs called the drug a promising direction but cautioned that the mouse-only study lacks human data on safety or efficacy. It also ran for a short time, so long-term effects remain unknown.